James Niedel is a Venture Partner and focuses on our biopharmaceuticals efforts. He was one of the founders of New Leaf in 2005, having moved with the healthcare team from Sprout, where he had been a venture partner since 2002. Prior to joining the venture industry, Jim was Chief Science and Technology Officer for GlaxoSmithKline and from 1995 to 2001 he was a member of the board of directors of Glaxo Wellcome plc with responsibility for Global Research and Development, Information Technology and Product Strategy. From 1988 to 1995, he was VP Research and SVP R&D for the US subsidiary of Glaxo.
Before joining the pharmaceutical industry, Jim was Professor of Medicine and Chief of the division of Clinical Pharmacology at Duke Medical School, where he had completed an Internal Medicine residency and a Hematology-Oncology fellowship. He received M.D. and Ph.D. (Biochemistry) degrees from the University of Miami, was selected a Searle Scholar, and is a Fellow of the Royal College of Physicians (London).
Jim also serves on the Scientific Advisory Board of the Tri-Institutional Therapeutics Discovery Institute (Tri-TDI) formed by Weill Cornell Medical College , the Rockefeller University and Memorial Sloan-Kettering Cancer Center, in partnership with Takeda Pharmaceutical Company.
Board Seats and Investments
Notable Alumni Investments
Chimerix (NASDAQ: CMRX)
Oriel Therapeutics (Acquired by Sandoz)
Pearl Therapeutics (Acquired by AstraZeneca)
Sirna Therapeutics (Acquired by Merck)